{"id":23780,"date":"2023-04-30T04:58:00","date_gmt":"2023-04-29T20:58:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=23780"},"modified":"2023-04-30T05:55:53","modified_gmt":"2023-04-29T21:55:53","slug":"bmj%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e9%ba%bb%e9%86%89%e8%8d%af%e7%89%a9%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%88%90%e4%ba%ba%e6%80%a5%e6%80%a7%e9%9d%9e%e7%89%b9%e5%bc%82%e6%80%a7","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=23780","title":{"rendered":"[BMJ\u53d1\u8868\u8bba\u6587]\uff1a\u9ebb\u9189\u836f\u7269\u7528\u4e8e\u6cbb\u7597\u6210\u4eba\u6025\u6027\u975e\u7279\u5f02\u6027\u8170\u75db\u7684\u7597\u6548\u53ca\u5b89\u5168\u6027"},"content":{"rendered":"\n

Research<\/strong><\/p>\n\n\n\n

Comparative effectiveness and safety of analgesic medicines for adults with acute non-specific low back pain: systematic review and network meta-analysis<\/h1>\n\n\n\n

Michael A Wewege<\/a>, Matthew K Bagg<\/a>, Matthew D Jones<\/a>,\u00a0et al<\/h3>\n\n\n\n

BMJ<\/em>\u00a02023;\u00a0380\u00a0doi:\u00a0https:\/\/doi.org\/10.1136\/bmj-2022-072962<\/a>\u00a0(Published 22 March 2023)Cite this as:\u00a0BMJ<\/em>\u00a02023;380:e072962<\/h3>\n\n\n\n

Abstract<\/h2>\n\n\n\n

Objective<\/strong> To evaluate the comparative effectiveness and safety of analgesic medicines for acute non-specific low back pain.<\/p>\n\n\n\n

Design<\/strong> Systematic review and network meta-analysis.<\/p>\n\n\n\n

Data sources<\/strong> Medline, PubMed, Embase, CINAHL, CENTRAL, ClinicalTrials.gov, clinicialtrialsregister.eu, and World Health Organization\u2019s International Clinical Trials Registry Platform from database inception to 20 February 2022.<\/p>\n\n\n\n

Eligibility criteria for study selection<\/strong> Randomised controlled trials of analgesic medicines (eg, non-steroidal anti-inflammatory drugs, paracetamol, opioids, anti-convulsant drugs, skeletal muscle relaxants, or corticosteroids) compared with another analgesic medicine, placebo, or no treatment. Adults (\u226518 years) who reported acute non-specific low back pain (for less than six weeks).<\/p>\n\n\n\n

Data extraction and synthesis<\/strong> Primary outcomes were low back pain intensity (0-100 scale) at end of treatment and safety (number of participants who reported any adverse event during treatment). Secondary outcomes were low back specific function, serious adverse events, and discontinuation from treatment. Two reviewers independently identified studies, extracted data, and assessed risk of bias. A random effects network meta-analysis was done and confidence was evaluated by the Confidence in Network Meta-Analysis method.<\/p>\n\n\n\n

Results<\/strong> 98 randomised controlled trials (15\u2009134 participants, 49% women) included 69 different medicines or combinations. Low or very low confidence was noted in evidence for reduced pain intensity after treatment with tolperisone (mean difference \u221226.1 (95% confidence intervals \u221234.0 to \u221218.2)), aceclofenac plus tizanidine (\u221226.1 (\u221238.5 to \u221213.6)), pregabalin (\u221224.7 (\u221234.6 to \u221214.7)), and 14 other medicines compared with placebo. Low or very low confidence was noted for no difference between the effects of several of these medicines. Increased adverse events had moderate to very low confidence with tramadol (risk ratio 2.6 (95% confidence interval 1.5 to 4.5)), paracetamol plus sustained release tramadol (2.4 (1.5 to 3.8)), baclofen (2.3 (1.5 to 3.4)), and paracetamol plus tramadol (2.1 (1.3 to 3.4)) compared with placebo. These medicines could increase the risk of adverse events compared with other medicines with moderate to low confidence. Moderate to low confidence was also noted for secondary outcomes and secondary analysis of medicine classes.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Conclusions<\/strong> The comparative effectiveness and safety of analgesic medicines for acute non-specific low back pain are uncertain. Until higher quality randomised controlled trials of head-to-head comparisons are published, clinicians and patients are recommended to take a cautious approach to manage acute non-specific low back pain with analgesic medicines.<\/p>\n\n\n\n

Systematic review registration<\/strong> PROSPERO CRD42019145257<\/p>\n","protected":false},"excerpt":{"rendered":"

Research Comparative effectiveness and safety of analge […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/23780"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23780"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/23780\/revisions"}],"predecessor-version":[{"id":23781,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/23780\/revisions\/23781"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}